Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...3334353637383940414243...143144»
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Two Cases of Robot-Assisted Total Pelvic Exenteration and Intracorporeal Ileal Conduit forLocally Advanced Rectal Cancer (Pubmed Central) -  Jul 1, 2022   
    He was started on bevacizumab+S-1/oxaliplatin therapy in July 2019...In April 2019, he was started on FOLFOXIRI+cetuximab therapy...At present, ie, at postoperative 12 months, the patient remains free of recurrence and metastasis, with a CEA level of 7.3 ng/ml and CA19-9 level of 12 U/ml. Ra-TPE, which allows transperineal removal of a specimen, can be performed as a minimally invasive surgery in combination with ICIC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Anktiva (inbakicept) / ImmunityBio
    Journal, Cancer stem cells:  Combinatorial Natural Killer Cell-based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells. (Pubmed Central) -  Jun 30, 2022   
    Flow cytometric analysis of a chordoma CSC population showed that CSCs expressed significantly more NK activating ligand B7-H6 and PD-L1 than non-CSCs, thus explaining a potential mechanism of selective targeting. These data suggest that chordoma may be effectively targeted by combinatorial NK cell-mediated immunotherapeutic approaches and that the efficacy of these approaches in chordoma and other CSC-driven tumor types should be investigated further in clinical studies.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion, Trial completion date:  Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer (clinicaltrials.gov) -  Jun 29, 2022   
    P2,  N=63, Completed, 
    In LALSCC nuclear PTHrP and absence of PTH1R expressions could be useful in predicting response and/or resistance to cetuximab in combined therapies, contributing to an aggressive behavior of tumor cells downstream to HER1. Active, not recruiting --> Completed | Trial completion date: May 2022 --> Aug 2021
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Clinical Trial,Phase III, Journal, Combination therapy:  The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab (Pubmed Central) -  Jun 28, 2022   
    Cetuximab in combination with chemotherapy is a standard first-line treatment regimen for patients with metastatic colorectal cancer (mCRC) RAS wild-type (wt); however, the efficacy of cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX) had never been demonstrated in a prospective, randomized, controlled phase III study. The TAILOR study is the first randomized, multicenter, prospective Phase III study evaluating the addition of cetuximab to FOLFOX in a RAS wt Chinese population and thus providing confirmatory data for the efficacy and safety of cetuximab plus FOLFOX versus FOLFOX alone.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Acquired resistance to EGFR-targeted therapy in quadruple wild-type colorectal cancer: role of glycation stress (Poster Area) -  Jun 28, 2022 - Abstract #EACR2022EACR_914;    
    Cetuximab (CTX) is the most used anti-EGFR targeted therapy in CRC...Conclusion Our data point to a novel connection between MG stress and acquired resistance to CTX in CRC. Ongoing analysis of MG stress level in organoid models will help evaluating the potential resensitizing effect of MG scavengers used alone or in combination with CTX in resistant CRC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Crosstalk Between PLCγ1 and Estrogen Receptor Modulates the Prognosis and Therapy Resistance of Luminal Breast Cancer (Poster Area) -  Jun 28, 2022 - Abstract #EACR2022EACR_665;    
    Our previous work showed that PLCγ1 induces cetuximab resistance in metastatic colorectal cancer by activating ERK and AKT pathways...Additionally, PLCγ1 KD was able to increase the sensitivity of cells to both tamoxifen and fulvestrant treatment...Conclusion Our results suggest an important role of PLCγ1 in estrogen-mediated signaling and hormone therapy resistance. These findings can have a significant impact on the prognosis and treatment of luminal BC patients and deserve further investigation.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Immune checkpoint ligand CD155 synergizes with anti-EGFR cetuximab to provoke a natural killer cell response to head and neck cancer. (Poster Area) -  Jun 28, 2022 - Abstract #EACR2022EACR_574;    
    Conclusion In conclusion, we show that blocking inhibitory signaling through CD155 synergizes with the approved EGFR-targeting cetuximab to generate a very potent response in vitro of NK cells to HNSCC cells, irrespective of their cetuximab resistance status. These data provide a preclinical rationale towards combining oncogenic and immune targeting agents in HNSCC to enhance the clinical efficiency of cetuximab treatment.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    p53 context-dependent role of miR-9/KLF5/SP1 axis in modulating response to therapy in Head and Neck Squamous Cell Carcinoma. (Poster Area) -  Jun 28, 2022 - Abstract #EACR2022EACR_488;    
    Radiotherapy (RT) plus Cetuximab (CTX) may represent an effective curative therapy for selected HPV-/TP53mut patients...Yet it re-sensitized TP53mut ones to this combination therapy. Conclusion We propose that the miR-9/KLF5/SP1/p53 axis may represent a novel potential prognostic/predictive marker for RT+CTX activity that could explain why only a subset of HNSCC patients benefits from RT+CTX therapy eventually stimulating the development of novel targeted approaches for resistant patients.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Metastases:  Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma (clinicaltrials.gov) -  Jun 24, 2022   
    P2,  N=78, Active, not recruiting, 
    Our data provide a rationale for clinical trials testing the combination of anti-EGF VacAbs with targeted inhibitors in MET amplified, MET Δ14 and KRAS G12C mutant NSCLC patients. Trial completion date: May 2022 --> May 2023
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Metastases:  FAMOSO: Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District (clinicaltrials.gov) -  Jun 22, 2022   
    P2,  N=10, Recruiting, 
    Trial completion date: Jun 2023 --> May 2025 | Trial primary completion date: Jun 2023 --> Apr 2024 Trial completion date: Dec 2021 --> Dec 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Estimation of Cumulative Activity of Lu-Cetuximab from a Single Diagnostic Cu-Cetuximab Scan. (Pubmed Central) -  Jun 19, 2022   
    Two independent equations are proposed for estimating Lu-cetuximab cumulative activity from an initial diagnostic Cu-cetuximab scan, when acquired at two relevant injection acquisition times, respectively. Applied to published tumor-bearing mouse data, the Cu-cetuximab SUR assessed at either 14 or 59 h postinjection turns out to be key metrics.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Purification and determination of antibody drugs in bio-samples by EGFR/cell membrane chromatography method. (Pubmed Central) -  Jun 15, 2022   
    The EGFR/CMC-online-ion exchange chromatography (IEC)/high performance liquid chromatography (HPLC) was established for the efficient purification and specific identification of cetuximab, nituzumab, and panizumab from cell culture medium and human serum...The EGFR/CMC-online-IEC/HPLC method has a high specificity, accuracy and sensitivity. Therefore, it will present a valuable method for the purification, identification, and analysis of monoclonal antibody drugs.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy. (Pubmed Central) -  Jun 15, 2022   
    In contrast to previous studies, cetuximab was not associated with lower rates of anemia after RT for nonmetastatic HNSCC patients compared to RT-alone. Dedicated prospective studies are needed to elucidate the effect of cetuximab on RT-induced anemia.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date:  Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases (clinicaltrials.gov) -  Jun 15, 2022   
    P3,  N=386, Recruiting, 
    Our data suggest that, despite the great clinical heterogeneity of HNSCC and the limited responders in the present cohort, the peripheral TCR repertoires from pretreatment PBMC may be developed as biomarkers for the benefit of immunotherapy in HNSCC. Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Tunable gold nanorod/NAO conjugates for selective drug delivery in mitochondria-targeted cancer therapy. (Pubmed Central) -  Jun 11, 2022   
    The addition of the monoclonal antibody Cetuximab to the conjugates enhanced their uptake within lung cancer cells and the conjugates were cytotoxic at subnanomolar concentrations (c ≈ 0.06 nM)...After intravenous administration in patient-derived xenografts (PDX) mouse models, the conjugates reduced the progression of EGFR-positive tumors. Overall, the NAO-AuNRs provide a promising strategy to realize membrane mitochondria-targeted conjugates for lung cancer therapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda, aderbasib (INCB7839) / Incyte
    Journal:  Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer. (Pubmed Central) -  Jun 11, 2022   
    Overall, the NAO-AuNRs provide a promising strategy to realize membrane mitochondria-targeted conjugates for lung cancer therapy. Our study shows that CRC resistance to EGFR inhibitors results primarily from the inability of the inhibitors to downregulate their target and that a PEPD-based combination treatment overcomes the resistance.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Nanocurcumin in Oral Squamous Cancer Cells and Its Efficacy as a Chemo-Adjuvant. (Pubmed Central) -  Jun 8, 2022   
    The combination treatment group had highly significant cell death (p <0.0001) compared to a single drug, and the NC sensitization caused substantial cell death compared to a single cetuximab treatment (p<0.01). Our study findings indicate the potential chemo-adjuvant effect of NC in oral cancer.